Advanced Enzyme Technologies Share Price

Conference Call with Advanced Enzyme Technologies Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 2 weeks 5 days ago

Biotechnology company Advanced Enzyme Technologies announced Q4FY26 & FY26 results Financial Highlights: Revenue from Operations: Reached Rs 2,034 million in Q4FY26, registering a growth of 22% YoY from Rs 1,672 million in Q4FY25, and an 18% QoQ increase from Rs 1,719 million in Q3FY26. For FY26, revenue increased by 17% YoY to Rs 7,458 million compared to Rs 6,369 million in FY25. EBITDA: Stood at Rs 632 million in Q4FY26, representing an increase of 39% YoY from Rs 456 million in Q4FY25, and higher by 28% QoQ compared to Rs 494 million in Q3FY26. For FY26, EBITDA grew by 18% YoY to Rs 2,291 million from Rs 1,944 million in FY25. EBITDA Margin: Maintained at 31% in Q4FY26 (up from 27% in Q4FY25 and 29% in Q3FY26). For FY26, the margin remained stable at 31%. Profit Before Tax (PBT): Clocked at Rs 598 million in Q4FY26, an increase of 38% YoY against Rs 435 million in Q4FY25, and up 3% QoQ from Rs 583 million in Q3FY26. FY26 PBT stood at Rs 2,325 million, growing 24% YoY from Rs 1,874 million in FY25. Profit After Tax (PAT): Surged by 69% YoY to Rs 453 million in Q4FY26 from Rs 267 million in Q4FY25, and recorded a 5% QoQ growth from Rs 432 million in Q3FY26. For FY26, PAT increased by 30% YoY to Rs 1,736 million from Rs 1,340 million in FY25. Earnings Per Share (EPS): Stood at Rs 3.84 in Q4FY26 (up 62% YoY from Rs 2.37 in Q4FY25 and up 1% QoQ from Rs 3.80 in Q3FY26). For FY26, EPS increased by 29% YoY to Rs 15.08 compared to Rs 11.72 in FY25. Business & Segment Highlights: Segment-wise Performance: Human Nutrition: Reached Rs 4,674 million, a 15% YoY growth. Animal Nutrition: Demonstrated robust growth of 25% YoY to Rs 946 million. Bio-Processing: Grew by 16% YoY to Rs 1,176 million. Specialized Manufacturing: Contributed 9% to total revenue, growing by 23% YoY to Rs 662 million. Geographical Revenue: Domestic Sales: Accounted for 52% of total revenue in Q4FY26 at Rs 1,061 million (up 51% YoY and 32% QoQ). For FY26, domestic sales amounted to Rs 3,727 million, representing a 28% YoY increase. International Sales: Accounted for 48% of total revenue in Q4FY26 at Rs 973 million (up 1% YoY and 6% QoQ). For FY26, international sales contributed Rs 3,731 million, reflecting an 8% YoY growth. Operational & Strategic Updates: The company launched its own nutraceutical brand, 'Wellfa', targeting Indian consumers to expand its B2C presence in the Human Nutrition sector. Maintained its status as a zero-debt entity, having successfully completed four acquisitions over the past nine years financed entirely through internal accruals. In the Baking segment, the company submitted 15 dossiers to the European Food Safety Authority (EFSA) and has received positive opinions for 9 of them. Result PDF

• Trendlyne
• 2 weeks 6 days ago

Biotechnology company Advanced Enzyme Technologies announced Q3FY26 results Revenue from operations on a consolidated basis increased to Rs 1,719 million in the Q3FY26 from Rs 1,691 million in the Q3FY25, a growth of 2%. Consolidated EBITDA during Q3FY26 stands at Rs 494 million as compared to Rs 553 million during Q3FY25, a decrease of 11%. Profit before tax stands at Rs 583 million during Q3FY26 as against Rs 530 million in Q3FY25, an increase of 10%. Profit after tax grew by 11% and stands at Rs 432 million during Q3FY26 as compared to Rs 389 million during Q3FY25. EBITDA margin stands at 29%, PBT margin stands at 34%, and PAT margin stands at 25% during the quarter. Financial costs stood at Rs 6 million during Q3FY26 as against Rs 9 million in Q3FY25. Depreciation and Amortization charge for the Q3FY26 stood at Rs 102 million as compared to Rs 90 million in Q3FY25. Earnings Per Share during Q3FY26 stand at Rs 3.80 as compared to Rs 3.36 in Q3FY25. Result PDF

• Trendlyne
• 3 months 4 weeks ago